Research study, conducted in patients with chronic hepatitis B, during treatment with nucleos(t)ide analogues (NA), with the aim to assess the effect of the administration of peginterferon alfa-2a (PEG-IFN) for 48 weeks, on the improvement of treatment responses.

Registry ID

EUCTR2012-000080-25

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

ROCHE

Start date

2012-09-07

Last update

2026-08-16

Conditions

• Chronic Hepatitis B

Summary

Serum HBsAg decline at the end of PEG-IFN plus NA combination treatment (Study Week 48).

Locations

• , , Italy

Related clinical trials

• A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
• VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
• A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
• Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
• A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
• Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

View on source registry